Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 5/20 | 0.72 |
| ▸ | HSD17B1 | P14061 | 3/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | RECQL | P46063 | 1/20 | 0.72 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.72 |
| ▸ | ESR1 | P03372 | 5/20 | 0.67 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.61 |
| ▸ | STS | P08842 | 6/20 | 0.59 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.58 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.58 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.58 |
| ▸ | SLCO1B1 | Q9Y6L6 | 1/20 | 0.58 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.57 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.57 |
| ▸ | PGR | P06401 | 2/20 | 0.57 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.57 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6466708 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL544801 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL5679557 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL12473458 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL16140032 | 1.00 | LMNA (0.72) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL9643150 | 0.90 | LMNA (0.71) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL9643950 | 0.90 | LMNA (0.71) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL11753160 | 0.88 | LMNA (0.71) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL11753152 | 0.88 | LMNA (0.71) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL17817040 | 0.86 | ESR1 (0.66) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109053846-B | Method for preparing ulipristal bisketal acetate | 台州仙琚药业有限公司 | 2020-01-07 | — | — | CN | disclosed |
| EP-3052513-B1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ULIPRISTAL ACETATE AND ITS 4'-ACETYL ANALOGUE | RICHTER GEDEON NYRT (HU) | 2018-12-05 | — | — | EP | disclosed |
| EP-2774933-B1 | ULIPRISTAL ACETATE PREPARATION METHOD AND INTERMEDIATE THEREOF | UTOPHARM (SHANGHAI) CO LTD (CN) | 2018-02-21 | — | — | EP | disclosed |
| US-9676814-B2 | Industrial process for the synthesis of ulipristal acetate and its 4′-acetyl analogue | RICHTER GEDEON NYRT. (HU) | 2017-06-13 | — | — | US | disclosed |
| US-20160311849-A1 | Industrial Process for the Synthesis of Ulipristal Acetate and its 4'-Acetyl Analogue | RICHTER GEDEON NYRT. (HU) | 2016-10-27 | — | — | US | disclosed |
| EP-3052513-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ULIPRISTAL ACETATE AND ITS 4'-ACETYL ANALOGUE | Richter Gedeon Nyrt. (HU) | 2016-08-10 | — | — | EP | disclosed |
| US-9163058-B2 | Method for preparing ulipristal acetate and key intermediate thereof | UTOPHARM (SHANGHAI) CO., LTD (CN) | 2015-10-20 | — | — | US | disclosed |
| WO-2015049637-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF ULIPRISTAL ACETATE AND ITS 4'-ACETYL ANALOGUE | RICHTER GEDEON NYRT. (HU) | 2015-04-09 | — | — | WO | disclosed |
| US-20140296510-A1 | Method for preparing ulipristal acetate and key intermediate thereof | Changzhou Siyao Pharm Co., Ltd. (CN) | 2014-10-02 | — | — | US | disclosed |
| EP-2774933-A1 | ULIPRISTAL ACETATE PREPARATION METHOD AND INTERMEDIATE THEREOF | Utopharm (Shanghai) Co., Ltd (CN) | 2014-09-10 | — | — | EP | disclosed |
| WO-2007144674-A1 | INDUSTRIAL PROCESS FOR THE SYNTHESIS OF 17α-ACETOXY-11β-[4-(N,N-DIMETHYL-AMINO)- PHENYL]-19-NORPREGNA-4,9-DIENE-3,20-DIONE AND NEW INTERMEDIATES OF THE PROCESS | RICHTER GEDEON NYRT (HU) | 2007-12-21 | — | — | WO | disclosed |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | NATIONAL INSTITUTES OF HEALTH | 2005-06-30 | — | — | US | disclosed |
| EP-1265911-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2002-12-18 | — | — | EP | disclosed |
| WO-2001074840-A2 | 17-ALPHA-SUBSTITUTED-11-BETA-SUBSTITUTED-4-ARYL AND 21-SUBSTITUTED 19-NORPREGNA 21-SUBSTITUTED 19-NORPREGNADIENEDIONE AS ANTIPROGESTATIONAL AGENTS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY OF HEALTH AND HUMAN SERVICES (US) | 2001-10-11 | — | — | WO | disclosed |
| EP-0422100-B1 | 11 BETA-SUBSTITUTED PROGESTERONE ANALOGS | RES TRIANGLE INST (US) | 1997-03-12 | — | — | EP | disclosed |
| EP-0422100-A4 | — | — | 1994-04-27 | — | — | EP | disclosed |
| US-5073548-A | Antiprogestational, progestational and antiglucocorticoid activity; glandular disorders; vision defects; antifertility agents | RESEARCH TRIANGLE INSTITUTE (US) | 1991-12-17 | — | — | US | disclosed |
| EP-0422100-A1 | 11-g(b)-SUBSTITUTED PROGESTERONE ANALOGS. | RES TRIANGLE INST (US) | 1991-04-17 | — | — | EP | disclosed |
| US-4954490-A | HORMONE INHIBITORS | RESEARCH TRIANGLE INSTITUTE (US) | 1990-09-04 | — | — | US | disclosed |
| WO-1989012448-A1 | 11beta-SUBSTITUTED PROGESTERONE ANALOGS | RESEARCH TRIANGLE INSTITUTE (US) | 1989-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311849-A1 | Industrial Process for the Synthesis of Ulipristal Acetate and its 4'-Acetyl Analogue | AADAC, NAT1, UBA1 | LMNA 3089/4885HSD17B1 684/4885MAPT 1859/4885 |
| US-20140296510-A1 | Method for preparing ulipristal acetate and key intermediate thereof | KIT, UGT1A4, CYP4A11 | LMNA 642/4885HSD17B1 531/4885MAPT 2896/4885 |
| US-20050143365-A1 | Structural modification of 19-norprogesterone I: 17-alpha-substituted-11-beta-substituted-4-aryl and 21-substituted 19-norpregnadienedione as new antiprogestational agents | HSD17B11, NR5A1, CYP19A1 | LMNA 384/4885HSD17B1 21/4885MAPT 4803/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.